Puma Biotechnology
PBYI· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +95.1% in FY2025
Alan H. Auerbach is the CEO of Puma Biotechnology and was paid $3.1M in FY2025 (Dec), down 23%.
Pay$100 in the stock at the end of FY20 → $58
Executives4
See all- 1Alan H. AuerbachPresident and Chief Executive OfficerFY2025
- 2Jeff J. LudwigChief Commercial OfficerFY2025
- 3Maximo F. NouguesChief Financial OfficerFY2025
- 4Douglas Hunt, B.Sc (Hons)Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allPuma Biotechnology paid its 4 named executives $6.8M in total in FY2025 (Dec). CEO Alan H. Auerbach was paid $3.1M of that.
| Name | |||
|---|---|---|---|
| Alan H. AuerbachPresident and Chief Executive Officer | |||
| Jeff J. LudwigChief Commercial Officer | |||
| Maximo F. NouguesChief Financial Officer | |||
| Douglas Hunt, B.Sc (Hons)Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See all
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Alan H. AuerbachChair · 15 yr on the boardNot independent—Paid as an executive
- Jay M. MoyesLead independent director · 13 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
